Yamahara Naoki, Takekoshi Akira, Kimura Akio, Shimohata Takayoshi
Department of Neurology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan.
Brain Sci. 2024 Oct 9;14(10):1012. doi: 10.3390/brainsci14101012.
Advances in diagnostic procedures have led to an increasing rate of diagnosis of autoimmune encephalitis or paraneoplastic neurological syndrome (AE/PNS) among patients with progressive supranuclear palsy (PSP)-like manifestations.
In this narrative review, we first discuss the clinical characteristics of AE/PNS in comparison to those of PSP, followed by a discussion of diagnosis and treatment.
The antibodies involved in these conditions include anti-IgLON5, -Ma2, and -Ri antibodies, each of which has a characteristic clinical presentation. The steps in the diagnosis of AE/PNS in patients with PSP-like manifestations include (i) suspicion of AE/PNS based on clinical presentations atypical of PSP and (ii) antibody detection measures. Methods used to identify antibodies include a combination of tissue-based assays and confirmatory tests. The primary confirmatory tests include cell-based assays and immunoblotting. Treatments can be divided into immunotherapy and tumor therapies, the former of which includes acute and maintenance therapies.
One of the major challenges of diagnosis is that existing reports on PSP-like patients with AE/PNS include only case reports, with the majority discussing antibodies other than anti-IgLON5 antibody. As such, more patients need to be evaluated to establish the relationship between antibodies and PSP-like manifestations.
诊断程序的进展导致在具有进行性核上性麻痹(PSP)样表现的患者中,自身免疫性脑炎或副肿瘤性神经系统综合征(AE/PNS)的诊断率不断上升。
在这篇叙述性综述中,我们首先将AE/PNS的临床特征与PSP的临床特征进行比较,然后讨论诊断和治疗。
这些病症所涉及的抗体包括抗IgLON5、抗Ma2和抗Ri抗体,每种抗体都有其特征性临床表现。对具有PSP样表现的患者进行AE/PNS诊断的步骤包括:(i)基于PSP非典型临床表现怀疑AE/PNS;(ii)抗体检测措施。用于识别抗体的方法包括基于组织的检测和确证试验相结合。主要的确证试验包括基于细胞的检测和免疫印迹。治疗可分为免疫治疗和肿瘤治疗,前者包括急性治疗和维持治疗。
诊断的主要挑战之一是,现有关于患有AE/PNS的PSP样患者的报告仅为病例报告,大多数报告讨论的是抗IgLON5抗体以外的抗体。因此,需要评估更多患者以确定抗体与PSP样表现之间的关系。